Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

According to research, one vial of Humalog (insulin lispro) cost $21 in 1999, but this increased to $332 in 2019, representing a price increase of 1480%. For its part, PhRMA, a trade group ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes ...

After hours: 7:59:51 pm GMT-5 ...